BRPI0509588A - derivados e tetraidronaftiridina e um processo para preparação dos mesmos - Google Patents

derivados e tetraidronaftiridina e um processo para preparação dos mesmos

Info

Publication number
BRPI0509588A
BRPI0509588A BRPI0509588-3A BRPI0509588A BRPI0509588A BR PI0509588 A BRPI0509588 A BR PI0509588A BR PI0509588 A BRPI0509588 A BR PI0509588A BR PI0509588 A BRPI0509588 A BR PI0509588A
Authority
BR
Brazil
Prior art keywords
derivatives
tetrahydronaphthyridine
alkyl
optionally substituted
preparing same
Prior art date
Application number
BRPI0509588-3A
Other languages
English (en)
Inventor
Hitoshi Kubota
Yoshinori Nakamura
Takanori Higashijima
Yasuo Yamamoto
Kozo Oka
Shigeki Igarashi
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of BRPI0509588A publication Critical patent/BRPI0509588A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

DERIVADOS DE TETRAIDRONAFTIRIDINA E UM PROCESSO PARA PREPARAçãO DOS MESMOS. Um novo composto da fórmula (I): em que R¬ 1¬ é alcoxicarbonila ou similares; R¬ 2¬ é alquila ou similares; R¬ 3¬ é hidrogênio ou similares; R¬ 4¬ é alquileno ou similares; R¬ 5¬ é grupo heterocíclico opcionalmente substituído; R¬ 6¬, R¬ 7, e R¬ 8¬ são independentemente hidrogênio; alquila, alcóxi, ou similares; R¬ 10¬ é anel aromático opcionalmente substituído, ou similares; ou um sal farmaceuticamente aceitável deste, o qual tem uma atividade inibidora contra proteína de transferência de éster de colesterila (CETP).
BRPI0509588-3A 2004-04-02 2005-04-01 derivados e tetraidronaftiridina e um processo para preparação dos mesmos BRPI0509588A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004109551 2004-04-02
PCT/JP2005/006895 WO2005095395A2 (en) 2004-04-02 2005-04-01 Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors

Publications (1)

Publication Number Publication Date
BRPI0509588A true BRPI0509588A (pt) 2007-09-25

Family

ID=35064445

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509588-3A BRPI0509588A (pt) 2004-04-02 2005-04-01 derivados e tetraidronaftiridina e um processo para preparação dos mesmos

Country Status (18)

Country Link
US (1) US7781443B2 (pt)
EP (1) EP1732924B1 (pt)
JP (1) JP4633731B2 (pt)
KR (1) KR100874623B1 (pt)
CN (1) CN100441579C (pt)
AR (1) AR048362A1 (pt)
AU (1) AU2005228291B2 (pt)
BR (1) BRPI0509588A (pt)
CA (1) CA2560008C (pt)
IL (1) IL178194A0 (pt)
MX (1) MXPA06011416A (pt)
MY (1) MY139887A (pt)
NO (1) NO20065012L (pt)
NZ (1) NZ550267A (pt)
RU (1) RU2356902C2 (pt)
TW (1) TWI345568B (pt)
WO (1) WO2005095395A2 (pt)
ZA (1) ZA200607782B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070208003A1 (en) * 2004-03-26 2007-09-06 Bell Michael G Compounds and methods for treating dyslipidemia
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
CN101443006B (zh) 2004-12-31 2012-10-10 雷迪美国治疗股份有限公司 作为cetp抑制剂的新颖的苄胺衍生物
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7652023B2 (en) 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
PE20071025A1 (es) * 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
US7659271B2 (en) 2007-04-13 2010-02-09 Kowa Company, Ltd. Pyrimidine compound having dibenzylamine structure and medicament comprising the same
SI2207775T1 (sl) 2007-11-05 2012-05-31 Novartis Ag benzilamino karboksiacil piperidinski derivati kot inhibitorji CETP uporabni za zdravljenje bolezni kot je hiperlipidemija ali arterioskleroza
CN101878199B (zh) * 2007-12-03 2013-09-18 诺瓦提斯公司 用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1，2-二取代的-4-苄基氨基-吡咯烷衍生物
MX2011001887A (es) 2008-08-22 2011-04-04 Baxter Int Derivados de bencil carbonato polimericos.
RU2012114770A (ru) * 2009-09-04 2013-10-10 Вандербилт Юниверсити АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ
AU2010323227B2 (en) * 2009-11-27 2015-11-19 Adverio Pharma Gmbh Method for producing methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate and its purification for use thereof as pharmaceutical substance
WO2012105574A1 (ja) * 2011-01-31 2012-08-09 国立大学法人長崎大学 光学活性化合物又はその塩の製造方法
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
KR101803866B1 (ko) 2011-09-27 2017-12-04 닥터 레디스 레보러터리즈 리미티드 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체
TWI570118B (zh) * 2012-01-06 2017-02-11 第一三共股份有限公司 經取代之吡啶化合物的酸加成鹽
US9067937B2 (en) 2012-01-19 2015-06-30 Oncotherapy Science, Inc. 1,5-naphthyridine derivatives and MELK inhibitors containing the same
EP2919785A4 (en) 2012-11-16 2016-10-05 Biocryst Pharm Inc ANTIVIRAL NUCLEOSIDES CONTAINING AZASUCRE
KR20190092539A (ko) 2016-12-16 2019-08-07 바스프 에스이 살충 화합물
EA039880B1 (ru) * 2017-05-30 2022-03-23 Дот Терапьютикс-1, Инк. Способ получения оптически активного соединения
CN107245074B (zh) * 2017-06-20 2019-04-09 牡丹江医学院附属红旗医院 用于治疗脑梗死的化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
BR0307332A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
US20070208003A1 (en) * 2004-03-26 2007-09-06 Bell Michael G Compounds and methods for treating dyslipidemia

Also Published As

Publication number Publication date
JP4633731B2 (ja) 2011-02-16
AU2005228291B2 (en) 2008-06-26
KR100874623B1 (ko) 2008-12-17
CA2560008A1 (en) 2005-10-13
US7781443B2 (en) 2010-08-24
EP1732924B1 (en) 2012-11-28
EP1732924A2 (en) 2006-12-20
ZA200607782B (en) 2008-02-27
WO2005095395A3 (en) 2006-06-01
WO2005095395A2 (en) 2005-10-13
CN100441579C (zh) 2008-12-10
RU2356902C2 (ru) 2009-05-27
TW200536853A (en) 2005-11-16
MY139887A (en) 2009-11-30
KR20060132966A (ko) 2006-12-22
AU2005228291A1 (en) 2005-10-13
US20070032485A1 (en) 2007-02-08
NZ550267A (en) 2009-08-28
JP2007530444A (ja) 2007-11-01
CN1938301A (zh) 2007-03-28
CA2560008C (en) 2010-06-01
TWI345568B (en) 2011-07-21
NO20065012L (no) 2006-12-28
RU2006138597A (ru) 2008-05-10
IL178194A0 (en) 2006-12-31
MXPA06011416A (es) 2006-12-20
AR048362A1 (es) 2006-04-19

Similar Documents

Publication Publication Date Title
BRPI0509588A (pt) derivados e tetraidronaftiridina e um processo para preparação dos mesmos
BRPI0509364A (pt) derivados de tetraidroquinolina e um processo por preparar os mesmos
DE69912581D1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
NO20054195L (no) Isoksazolforbindelser som inhibitorer for varmesjokkproteiner
DE60304059D1 (de) 3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäureamid derivate als hsp90 inhibitoren zur behandlung von krebs
WO2001019788A3 (en) BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
IL156873A0 (en) Pharmaceutically active piperidine derivatives
ATE404536T1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
BRPI0411285A (pt) composto, processo para preparar um composto formulação farmacêutica, uso de um composto, e, método de prevenção ou tratamento de distúrbios
EP1020452A4 (en) benzimidazole derivatives
BR0307033A (pt) ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas
NO973213L (no) Nye 2-(1H)-quinolinforbindelser, fremgangsmåter ved fremstilling av slike samt farmasöytiske sammensetninger omfattende disse
AU6220300A (en) Benzofurylpiperazine serotonin agonists
BRPI0411308A8 (pt) Composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
BR0014314A (pt) Processo para derivados de ácido fenilacético
PT1303514E (pt) Processo para preparacao de azacicloalcanoilaminotiazoles
EA200600601A1 (ru) Производные аминопиридина в качестве ингибиторов индуцируемой no-синтазы
AU4424401A (en) Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
ES2165193T3 (es) Metodo para aumentar la actividad de una enzima.
EP1211253A4 (en) DIHYDROBENZOFURAN TRICYCLIC DERIVATIVES, THEIR PREPARATION METHOD AND AGENTS
MXPA02011352A (es) Nuevos derivados de benzofurano.
HUP0302473A2 (hu) Új benzotiofénszármazékok
ATE469156T1 (de) 3,4 diaminopyridin-derivate
EA200500028A1 (ru) Новые соединения 3-(4-оксо-4h-хромен-2-ил)-(1h)-хинолин-4-она, способ их получения и фармацевтические композиции, которые их содержат
ATE423772T1 (de) Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MITSUBISHI TANABE PHARMA CORPORATION (JP)

Free format text: ALTERADO DE: TANABE SEIYAKU CO., LTD.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.